NCT07263542

Brief Summary

This randomized controlled trial will evaluate motor development outcomes in children aged 5-12 years with dyskinetic cerebral palsy. The Primary Outcome measures will be Gross motor development, gait, trunk control, balance, and coordination, and will be assessed using the Shoaib Sensorimotor Development Tool (SMDT), Gross Motor Function Measure-88 (GMFM-88), Jacks' observational Gait Analysis scale, Trunk Impairment Scale (TIS), Time Up and Go Test, and Heel-to-Shin test. The fine motor development as a secondary outcome measure will be assessed using the Box and Block Test (BBT). Before allocating participants within the study, informed consent will be obtained to ensure rigorous adherence to the Principles of Ethical Research as outlined in the Helsinki Declaration for Ethical Research. Baseline readings will be recorded using the selected tools against the pre-defined outcome measures. Randomization will be done through an online tool, and the Participants will be divided into two intervention arms. The control group will receive conventional Bobath therapy, and the experimental group will undergo body weight-supported treadmill training (BWSTT), with both interventions administered over a period of 4 weeks, 5 days a week. Each session will be structured as follows: 5 minutes of warm-up exercises to prepare the body, followed by a 30-minute core treatment session focused on therapeutic interventions, concluding with 5 minutes of cooldown exercises to promote recovery and relaxation. This sequence ensures a balanced approach while maintaining the total session duration of 40 minutes, 5 days a week for 4 weeks. Statistical analysis of the results will be conducted using SPSS software to determine the significance of the findings. The Shapiro-Wilk test will be employed to determine the normality of the data. If the data distribution is normal, an independent t-test will be employed for between-group comparison; otherwise, non-parametric alternatives will be applied. Within group analysis, a paired t-test will be applied to evaluate differences and the results will be reported.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
1mo left

Started Dec 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Dec 2025Jun 2026

First Submitted

Initial submission to the registry

November 16, 2025

Completed
18 days until next milestone

First Posted

Study publicly available on registry

December 4, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

December 10, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2026

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 10, 2026

Expected
Last Updated

December 4, 2025

Status Verified

November 1, 2025

Enrollment Period

4 months

First QC Date

November 16, 2025

Last Update Submit

November 23, 2025

Conditions

Keywords

cerebral palsy, BWSTT, DCP, RCT

Outcome Measures

Primary Outcomes (6)

  • Gross motor Development

    Gross Motor Development will be analyzed using GMFM-88. The tool categorizes motor development into five domains: lying and rolling, sitting, crawling and kneeling, standing, and walking, running, and jumping. These domains encompass 88 items, each scored on a 4-point ordinal scale ranging from 0 (indicating the inability to initiate the movement) to 3 (representing task completion). Higher scores reflect greater motor development in the patient.

    4 weeks

  • Gross motor Development

    Gross Motor Development will be analyzed using the Shoaib sensorimotor Development Tool. The standardized protocol comprises 72 developmentally stratified items employing a tripartite scoring matrix (0, 0.5, 1). The maximum attainable score is 72, while a score below 36 predicts atypical development.

    4 weeks

  • Gait analysis

    Gait analysis will be conducted using Jacks' Observational Gait Analysis. It is a qualitative assessment instrument designed for the systematic identification of pathokinematic deviations from normal gait patterns across the entire cycle. Instead of employing an ordinal quantification system, it employs a comparative observational framework where abnormalities are evaluated against established normative biomechanical parameters.

    4 week

  • trunk control

    Trunk Control assessment will be done using Trunk Impairment Scale. It assesses trunk control in three key domains: static sitting balance (ability to maintain upright posture), dynamic sitting balance (weight-shifting and reaching), and coordination (rotational movements). Scoring ranges from 0 (severe impairment) to 23 (normal function), providing quantitative data for rehabilitation progress tracking

    4 weeks

  • Dynamic Balance and functional mobility

    The balance will be assessed using Time up and Go Test. Key metrics measured are the time taken to stand, walk, turn, and sit. Normal score falls between 10-12 seconds. The greater the time required to accomplish the task, the greater the gravity of the problem.

    4 weeks

  • motor coordination assessment

    Motor coordination assessment will be conducted through the standardized heel-shin coordination test to evaluate volitional limb control precision. Participants will be instructed to perform the maneuver in supine position by sliding the plantar aspect of one foot along the contralateral tibial crest, maintaining continuous contact from the tibial tuberosity to the lateral malleolus. The quality of the movement will be indicative of coordinated limb function. Jerky or clumsy movement and failure to perform it throughout the dictated range are indicative of neurological pathology.

    4 weeks

Secondary Outcomes (1)

  • Fine Motor Development

    4 weeks

Study Arms (2)

BWSTT

EXPERIMENTAL

Experimental group will recieve body weight supported treadmill training.

Other: BODY WEIGHT SUPPORTED TREADMILL TRAINING

BOBATH

ACTIVE COMPARATOR

comparator group will recieve Bobath therapy

Other: BOBATH THERAPY

Interventions

The experimental group, will receive BWSTT with 40% weight offloading and a treadmill speed of 0.4 miles per hour (mph) at the start of the treatment. Weight offloading will be progressively decreased by 10% each week, leading to 30% offloading in the 2nd week, with the treadmill speed adjusting to 0.8 mph, 20% offloading in the 3rd week, with speed increasing to 1.2 mph; and 10% offloading during the 4th week of the intervention at a speed of 1.6 mph, for 30 minutes a day, five days a week for four weeks.

BWSTT

The control group, will receive Bobath Therapy. The protocol will include dynamic balance training on a balance board for 6 minutes, followed by a 2-minute rest. Functional reaching and ball-throwing exercises for 6 minutes, followed by a 2-minute rest period. Supine pelvic bridging exercises for 6 minutes, followed by 2-minute rest intervals. weight-bearing exercises in sitting, standing, kneeling, and crawling positions to facilitate equal body weight transfers without disturbing postural control for another six minutes, followed by a 2-minute rest. Obstacle negotiation (cones, steps) with focus on: Heel-strike initiation, Stance-phase knee control, and Push-off symmetry for six minutes.

BOBATH

Eligibility Criteria

Age5 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • \- This study will include DCP Patients aged 5-12 years without any gender preference, falling at GMFCS levels I-II. The included participants must be capable of following instructions and must not have any known surgical or medical history.

You may not qualify if:

  • DCP patients having cardiac complications, Past surgical history, Mental retardation, visual and cognitive deficits, under another gait training protocol, Congenital musculoskeletal defects, dislocations of the hip, significant hip and knee contractures, Behavioral disorders, or a history of Recent botulinum toxin injections, or uncontrolled epilepsy will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Biological and Applied Sciences

Lahore, Punjab Province, 53,200, Pakistan

Location

MeSH Terms

Conditions

Cerebral Palsy

Condition Hierarchy (Ancestors)

Brain Damage, ChronicBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Hafsa Jamil, DPT

    Lahore University of Biological and Applied Sciences

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shaoib Waqas, P.hd

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
It will be a single-blinded RCT in which the outcome assessor will be kept blind about participants' allocation group. Assessor will be kept isolated from the intervention administration team.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The study utilizes parallel study design in which two groups will receive two different interventions. This design allows the comparison of two different treatment approaches under identical conditions.2
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
research supervisor

Study Record Dates

First Submitted

November 16, 2025

First Posted

December 4, 2025

Study Start

December 10, 2025

Primary Completion

April 10, 2026

Study Completion (Estimated)

June 10, 2026

Last Updated

December 4, 2025

Record last verified: 2025-11

Data Sharing

IPD Sharing
Will not share

Individual patient data (IDP) will not be disclosed to preserve patient confidentiality and comply with privacy protection protocols. Sharing raw datasets carries inherent risks, including potential misinterpretation of sensitive health information and unauthorized utilization by third parties, which could lead to non-consensual exploitation or breaches of ethical guidelines. To mitigate these concerns, aggregated or anonymized data will be provided in alignment with regulatory standards for transparency while safeguarding participant identities.

Locations